Table 1 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic availability
Medication | Monthly cost in gap | Monthly cost in catastrophic | |||||||
|---|---|---|---|---|---|---|---|---|---|
Median of state mean costs | Median of state mean costs | Median of state mean costs | |||||||
$, (Range of mean costs) | $, (Range of mean costs) | $, (Range of mean costs) | |||||||
2007 | 2010 | Change (%) | 2007 | 2010 | Change (%) | 2007 | 2010 | Change (%) | |
Arimidex | 39.64 (38.37-48.19) | 62.83 (60.00-74.75) | +58 | 258.64 (247.44-263.47) | 392.84 (375.66-418.58) | +52 | 13.18 (12.68-13.32) | 19.65 (19.03-20.93) | +49 |
Aromasin | 42.57 (40.72-50.94) | 86.50 (81.51-101.08) | +103 | 267.56 (255.21-273.62) | 353.98 (351.86-377.07) | +32 | 13.66 (13.07-13.79) | 17.70 (17.59-18.85) | +30 |
Femara | 41.92 (39.38-51.11) | 89.03 (80.95-102.77) | +112 | 277.65 (249.14-282.54) | 433.42 (430.46-461.42) | +56 | 14.16 (12.96-14.34) | 21.67 (21.55-23.07) | +53 |
Tamoxifen | 6.19 (5.95-9.22) | 5.98 (5.66-6.75) | −3 | 21.32 (20.36-25.42) | 15.52 (15.03-18.90) | −27 | 2.26 (2.20-2.70) | 2.60 (2.58-2.75) | +15 |